Nuvation Bio Inc.

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on oncology that entered the public markets through a business combination with Panacea Acquisition Corp. II (NASDAQ: PANA), a blank-check company sponsored by Panacea Holdings. The company filed its S-1 registration statement with the SEC on March 11, 2021, as part of the de-SPAC process. Following the completed merger, Nuvation Bio listed on the New York Stock Exchange under the ticker NUVB, with its pipeline centered on next-generation cancer therapeutics targeting novel oncology pathways. Founded by oncology veteran David Hung, the company has remained active in clinical development since going public. Sign up for SpacDesk to access the full filing history, sponsor details, and real-time analytics on this and hundreds of other SPAC transactions.